Arbutus Biopharma Corp
No SEC Form 4 filings for $ABUS in the last 30 days.
See all $ABUS insider activity →Arbutus and Genevant said they received about $178 million from Moderna under a March 2026 settlement. They also expanded US litigation against BioNTech and Pfizer to global Unified Patent Court claims over mRNA-LNP patents, seeking monetary relief and injunctions across multiple European countries. The UPC opposition hearing for one patent is set for Jan 2027.
Arbutus Biopharma (ABUS) reported Q2 2026 results and said the FDA aligned with its proposed Phase 2b trial design for imdusiran in chronic hepatitis B, following Fast Track designation. The company received about $178.4 million from its Moderna settlement share and plans potential share repurchases up to about $230 million. Q2 revenue was $1.0 million; net loss $5.1 million.
Arbutus Biopharma (Nasdaq: ABUS) reported Q2 2026 results, with cash, cash equivalents and marketable securities of $92.6M at June 30, 2026. Q2 revenue fell to $1.0M from $10.7M year over year, and net loss was $5.1M. In July it received $178.4M from a Moderna settlement, expects up to $230M in share repurchases, and aligned with the FDA on a Phase 2b imdusiran trial design.
Over the past 7 days, alphai's AI scored 4 news stories mentioning ABUS (Arbutus Biopharma Corp). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent ABUS coverage spans financial news, market movers and technology.
New UPC claim details and expanded enforcement raise ongoing legal overhang and potential settlement/injunction risk for ABUS.
FDA alignment reduces protocol uncertainty for imdusiran’s Phase 2b, supporting a clearer path to future efficacy/safety readouts.
Settlement cash inflow and FDA alignment on imdusiran Phase 2b are near-term catalysts, while revenue remains small and losses persist.
Near-term sentiment should be supported by the Moderna settlement cash inflow and the disclosed capital return plan, while fundamentals remain loss-making with low current revenue.
Settlement cash materially boosts ABUS profitability and liquidity, supporting near-term capital return expectations but leaving longer-term risk tied to legacy IP.
alphai scores every news story that mentions ABUS with an AI model for sentiment and relevance, and aggregates insider trades from Arbutus Biopharma Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Arbutus and Genevant said they received about $178 million from Moderna under a March 2026 settlement. They also expanded US litigation against BioNTech and Pfizer to global Unified Patent Court claims over mRNA-LNP patents, seeking monetary relief and injunctions across multiple European countries. The UPC opposition hearing for one patent is set for Jan 2027.
7 min readArbutus Biopharma (ABUS) reported Q2 2026 results and said the FDA aligned with its proposed Phase 2b trial design for imdusiran in chronic hepatitis B, following Fast Track designation. The company received about $178.4 million from its Moderna settlement share and plans potential share repurchases up to about $230 million. Q2 revenue was $1.0 million; net loss $5.1 million.
5 min readArbutus Biopharma (Nasdaq: ABUS) reported Q2 2026 results, with cash, cash equivalents and marketable securities of $92.6M at June 30, 2026. Q2 revenue fell to $1.0M from $10.7M year over year, and net loss was $5.1M. In July it received $178.4M from a Moderna settlement, expects up to $230M in share repurchases, and aligned with the FDA on a Phase 2b imdusiran trial design.
6 min readArbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first
6 min readArbutus Biopharma (ABUS) received about $178 million from Moderna (MRNA) as its share of a $950 million noncontingent LNP patent settlement, with reimbursement of legal costs and an expected Q3 dividend tied to Genevant. ABUS reported Q1 2026 revenue of $179.1 million and net income of $169.7 million. Moderna reported Q2 2026 revenue of $145 million and a net loss of $782 million, plus FDA approval for mFLUSIVA.
6 min readArbutus Biopharma (ABUS) and Genevant Sciences, a Roivant unit, filed three international patent lawsuits against Pfizer and BioNTech to enforce LNP patents tied to mRNA-LNP COVID-19 vaccines, seeking monetary relief and injunctions. Arbutus said it received about $178 million from Moderna under a settlement and expects a Genevant-parent dividend in Q3 2026, plus share repurchases up to about $230 million starting Q3 2026.
4 min readArbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Form 8-K False 0001447028 0001447028 2026-07-15 2026-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 8-K _________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the
3 min readSimply Wall St reports Arbutus Biopharma (ABUS) was added to the Russell 2000 Growth Defensive and Russell 2000 Defensive indexes and removed from certain Russell value indexes. The article cites ABUS at $5.14, with returns of 56.7% (1 year), 126.4% (3 years), and 94.0% (5 years), and notes analyst price target range $4.88 to $5.40.
3 min readTwo Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi have reported a beneficial ownership of 18,557,543 common shares, representing a 9.4% stake in Arbutus Biopharma Corporation (NASDAQ: ABUS). This stake is held through two funds: Two Seas Global (Master) Fund LP and Two Seas LNP Opportunities (Master) Fund LP. The reporting persons have sole voting and dispositive power over these shares, calculated based on 196,947,757 common shares outstanding as of March 31, 2026.
3 min readArbutus Biopharma Corporation announced that the U.S. FDA has granted Fast Track designation for imdusiran, a drug for chronic hepatitis B. This designation will facilitate the development and expedited review of imdusiran, which has shown potential to achieve functional cure in trials. The company plans to work closely with the FDA to advance the drug, addressing a significant unmet medical need for the over 250 million people affected by chronic HBV worldwide.
2 min read
